Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone65-6236-3388
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.70 million
Profitability
Miscellaneous
Employees168
OptionableOptionable
Wave Life Sciences (NASDAQ:WVE) Frequently Asked Questions
What is Wave Life Sciences' stock symbol?
Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."
How were Wave Life Sciences' earnings last quarter?
Wave Life Sciences Ltd (NASDAQ:WVE) announced its quarterly earnings results on Friday, November, 9th. The company reported ($1.28) earnings per share for the quarter, missing analysts' consensus estimates of ($1.26) by $0.02. The firm had revenue of $4.49 million for the quarter, compared to the consensus estimate of $5.36 million. Wave Life Sciences had a negative return on equity of 112.13% and a negative net margin of 1,114.49%. View Wave Life Sciences' Earnings History.
When is Wave Life Sciences' next earnings date?
What price target have analysts set for WVE?
5 brokerages have issued twelve-month price objectives for Wave Life Sciences' shares. Their forecasts range from $49.00 to $65.00. On average, they expect Wave Life Sciences' share price to reach $58.20 in the next twelve months. This suggests a possible upside of 42.6% from the stock's current price. View Analyst Price Targets for Wave Life Sciences.
What is the consensus analysts' recommendation for Wave Life Sciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Wave Life Sciences.
What are Wall Street analysts saying about Wave Life Sciences stock?
Here are some recent quotes from research analysts about Wave Life Sciences stock:
- 1. According to Zacks Investment Research, "WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. " (1/19/2019)
- 2. HC Wainwright analysts commented, "We value $49/share based on a risk-adjusted, sum-of-parts DCF analysis: beta of 0.69, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 6.6%, and tax rate of 15% beginning in FY 2027. We value $3/share, respectively, which together account for roughly 90% of our target with the remainder derived from FTD and ALS expected to enter the clinic during 2019. Risks to our target include: commercial, reimbursement, regulatory, along with clinical and manufacturing." (12/10/2018)
Has Wave Life Sciences been receiving favorable news coverage?
Media headlines about WVE stock have been trending very positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Wave Life Sciences earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Wave Life Sciences' key competitors?
Some companies that are related to Wave Life Sciences include FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Emergent Biosolutions (EBS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM) and Ultragenyx Pharmaceutical (RARE).
Who are Wave Life Sciences' key executives?
Wave Life Sciences' management team includes the folowing people:
- Dr. Paul B. Bolno, Pres, CEO & Director (Age 45)
- Dr. Christopher Francis Ph.D., Sr. VP of Corp. Devel. & Head of Emerging Areas (Age 41)
- Dr. Chandra Vargeese, Sr. VP of Drug Discovery (Age 58)
- Mr. Keith Regnante, Chief Financial Officer (Age 49)
- Mr. Kyle B. Moran, Sr. VP of Operations & Bus. Analytics (Age 48)
Who are Wave Life Sciences' major shareholders?
Wave Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Matisse Capital (0.15%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.
Which major investors are buying Wave Life Sciences stock?
How do I buy shares of Wave Life Sciences?
Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Wave Life Sciences' stock price today?
One share of WVE stock can currently be purchased for approximately $40.80.
How big of a company is Wave Life Sciences?
Wave Life Sciences has a market capitalization of $1.20 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.
What is Wave Life Sciences' official website?
How can I contact Wave Life Sciences?
Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]
MarketBeat Community Rating for Wave Life Sciences (NASDAQ WVE)
MarketBeat's community ratings are surveys of what our community members think about Wave Life Sciences and other stocks. Vote "Outperform" if you believe WVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
